Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Rating of “Hold” by Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $4.50.

Several equities analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Barclays restated an “equal weight” rating and issued a $1.00 price objective (down from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Wednesday, October 8th.

Sangamo Therapeutics Trading Down 1.6%

Shares of SGMO stock opened at $0.44 on Friday. The firm has a market capitalization of $149.07 million, a price-to-earnings ratio of -1.01 and a beta of 1.29. The business’s 50-day moving average price is $0.46 and its 200-day moving average price is $0.53. Sangamo Therapeutics has a 12 month low of $0.38 and a 12 month high of $1.40.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08). Sangamo Therapeutics had a negative net margin of 331.28% and a negative return on equity of 813.95%. The business had revenue of $0.58 million during the quarter, compared to the consensus estimate of $34.40 million. On average, sell-side analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Sangamo Therapeutics by 23.9% during the 3rd quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company’s stock valued at $7,817,000 after purchasing an additional 2,240,422 shares during the period. Two Sigma Investments LP boosted its stake in shares of Sangamo Therapeutics by 182.7% in the 3rd quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company’s stock valued at $1,669,000 after purchasing an additional 1,602,107 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Sangamo Therapeutics by 63.1% in the 3rd quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company’s stock valued at $2,466,000 after purchasing an additional 1,417,029 shares during the last quarter. Wasatch Advisors LP increased its position in shares of Sangamo Therapeutics by 17.7% during the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock worth $4,376,000 after buying an additional 1,215,653 shares during the period. Finally, Oracle Investment Management Inc. bought a new position in Sangamo Therapeutics during the third quarter worth $677,000. 56.92% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.